![Figure 4: Everolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts.](https://www.oncotarget.net/wp-content/uploads/2023/02/Screen-Shot-2023-02-09-at-10.27.10-AM-300x169.png)
Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway
February 9, 2023
we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February... read more